UroAlert - GU Oncology Daily

July 30, 2026

Videos

Peer-to-Peer Clinical Conversations

Single-Arm Trials and Hazard Ratio Interpretation in Non-Muscle-Invasive Bladder Cancer - Cathy Yuan

Cathy Yuan discusses the methodological basis for single-arm trials in BCG-unresponsive NMIBC and hazard ratio interpretation.

View

A Patient-Centered Toxicity Framework and Quality of Life in Adjuvant RCC - Elizabeth Nally

Elizabeth Nally shares a patient-derived toxicity framework developed from interviews with kidney cancer patients and applied to IMmotion010, a global phase 3 adjuvant trial.

View

Beyond the Abstracts

Time to Treatment Initiation and Survival in Patients With Muscle-Invasive Bladder Cancer (MIBC) - Beyond the Abstract

Incidence and Impact of Pseudoprogression and Mixed Responses in Metastatic Renal Cell Carcinoma Patients Treated with Ipilimumab/Nivolumab: A Retrospective Analysis - Beyond the Abstract

Conference Coverage

EAU 2026: Case-Based Panel Discussion High-Risk NMIBC Post-BCG Failure: Spare the Bladder? Bladder Sparing: Trial Overview ICB (Combinations)

ASCO GU 2026: First Results of a Dose-Escalation Study Evaluating CBM588 with Nivolumab + Ipilimumab in Metastatic RCC

ASCO GU 2026: A Phase II Study Evaluating the Efficacy and Safety of Perioperative EV + Toripalimab Combined with Endoscope-Based Kidney-Sparing Surgery for Patients with High-Risk UTUC (WUTSUP-04EV-JS001)

AUA 2026: Behind the Scenes of Leading Urology Clinical Trials: Perspectives of Running Clinical Trials as a Medical Oncologist in Academic Practice

APCCC 2026: Monitoring in mCRPC

Articles

Editor Selected Abstracts and Commentaries

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

UroAlert - GU Oncology Daily

Bladder Cancer

Penile & Urethral Cancers

Renal Cancer

Prostate Cancer

Upper Tract Tumors

Login